Summary
Eli Lilly and Company's 2010 10-K filing highlights a year of 6% revenue growth, reaching $23.08 billion, driven by key products like Alimta, Cymbalta, and insulin products, alongside a strong performance in its animal health division. Net income saw a significant increase of 17% to $5.07 billion, with earnings per share rising to $4.58. However, the report also flags upcoming patent expirations for major products such as Zyprexa (October 2011) and Cymbalta (2013), which are expected to lead to a "rapid and severe decline" in sales due to generic competition, posing a material risk to future financial performance. The company's R&D investment increased to $4.88 billion, reflecting its commitment to developing new medicines, with a robust pipeline across various therapeutic areas including diabetes, oncology, and Alzheimer's disease. Despite this investment, the company faces ongoing patent challenges and the increasing impact of healthcare reforms and pricing pressures globally. Lilly is actively managing these risks through collaborations and a focus on its patent-protected portfolio, but investors should be aware of the significant headwinds from patent cliffs in the near term.
Financial Highlights
54 data points| Revenue | $23.08B |
| Cost of Revenue | $4.37B |
| Gross Profit | $18.71B |
| R&D Expenses | $4.88B |
| SG&A Expenses | $7.05B |
| Interest Expense | $185.50M |
| Net Income | $5.07B |
| EPS (Basic) | $4.58 |
| EPS (Diluted) | $4.58 |
| Shares Outstanding (Basic) | 1.11B |
| Shares Outstanding (Diluted) | 1.11B |
Key Highlights
- 1Revenue increased by 6% to $23.08 billion in 2010, driven by strong performance from Alimta, Cymbalta, and insulin products, as well as the animal health segment.
- 2Net income rose by 17% to $5.07 billion, with earnings per share increasing to $4.58, reflecting effective cost management alongside revenue growth.
- 3Research and Development (R&D) expenses increased by 13% to $4.88 billion, signaling continued investment in pipeline development for new therapeutic areas.
- 4Major products like Zyprexa and Cymbalta are facing imminent patent expirations in key markets (e.g., Zyprexa in the US in October 2011), posing a significant risk of sales decline due to generic competition.
- 5The company is navigating the complexities of U.S. healthcare reform, which is expected to reduce revenue by $400 million to $500 million in 2011 due to increased rebates and fees.
- 6Lilly faces ongoing patent litigation for several key products, including Alimta, Cymbalta, and Strattera, with the outcomes having the potential for material impact.
- 7The company's financial condition remains strong, with cash and cash equivalents totaling $5.99 billion at the end of 2010, providing flexibility for operations and strategic initiatives.